Psychiatry

Patients with depression from high-wealth areas were 1.62 times more likely in primary care and 1.67 times more likely in psychiatry to use telehealth.

The FDA accepted the sNDA for risperidone (Uzedy) extended-release injectable suspension for the maintenance treatment of bipolar I disorder in adults.

Comorbid conditions accrued at a rate 30% faster among adults with depression than in those without the disorder over a 7-year follow-up period.

People with MDD demonstrated a preference for carbohydrate-rich foods and reduced reward from fat- and protein-rich foods, according to new research.

The first patient was dosed in the Panorama study assessing MM120 ODT, a form of LSD, for the treatment of GAD.

GH001, an inhalable 5-MeO-DMT therapy, led to a -15.5 MADRS score reduction by day 8 in patients with treatment-resistant depression.

Brexpiprazole and sertraline showed promise for PTSD treatment in a recent study. Lead author, Lori Davis, MD, discusses clinical findings, treatment guidelines, and future research directions.

Your daily dose of the clinical news you may have missed.

Data showed that brexpiprazole plus sertraline significantly improved PTSD symptoms vs sertraline alone. Lead author, Lori Davis, MD, discusses more.

The investigational and potentially first-in-class therapy may enhance AMPA receptor sensitivity to glutamate, enhancing neuronal transmission.

Findings on the efficacy of treatments for MDD include the favorable effects of exercise, of CBT, and the robust outcomes of ECT among neuromodulatory modalities.

The approval of esketamine follows an FDA Priority Review and is based on data showing that esketamine alone demonstrated rapid and superior improvement in depressive symptoms compared with placebo.

Your daily dose of the clinical news you may have missed.

A new analysis of patient reported outcomes from the PATHFINDER study indicate the potential clinical benefit of early cancer detection.

The acquisition brings lumateperone, known as Caplyta, and the clinical-stage agent ITI-1284, for generalized anxiety disorder and Alzheimer's agitation, into the J&J fold.

Your daily dose of the clinical news you may have missed.

An earlier phase 2 study found statistically significant improvement of MDD in female participants.

The adcomm meeting is expected to happen in the first half of 2025, and means the FDA expects to miss the target PDUFA date.

The failure of the novel kappa opioid receptor antagonist to best placebo in the first of triplicate phase 3 studies has Neumora concerned but not deterred.

Daily step counts of 5000 or more corresponded with fewer depressive symptoms, according to a recent systematic review and meta-analysis.

Substances of choice used in the previous 12 months were alcohol, nicotine vaping, and cannabis but the trends among the 8th, 10th, and 12th graders are very encouraging.

In the largest twin-sibling study to date of the inherited biological risk of PTSD, researchers found additive genetic and unique environmental effects contributed to the disorder.

New findings highlight the potential of this combination therapy as a new option for people with PTSD who have not responded to standard treatments.

A phase 1b and Phase 2 study are up next for the novel potential MDD treatment.

Intra-Cellular Therapies submitted an sNDA to the FDA for lumateperone for the treatment of MDD in adults as as adjunctive therapy to antidepressants.

Your daily dose of the clinical news you may have missed.

Approximately 70% of US adults surveyed hope their primary care clinician will ask about their mental health during an appointment, regardless of the presenting issue.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The FDA warnings were intended to increase physician monitoring for suicidal thoughts and behaviors but have had dramatic unintended consequences.